StockData
Guided Therapeutics Inc logo

Guided Therapeutics Inc (GTHP) shareholders

GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.16−0.03 (-15.79%)

Close on Oct 19, 2026Market cap $15.45MP/E –Yield –

Ownership

Who owns Guided Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Auctus Fund Management LLC
Joint filing with Auctus Fund, LLC (9.90%), Alfred Sollami (9.90%) and 1 more
5,804,8659.90%13G (passive) amendmentSep 30, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
John E. ImhoffDirector, 10% owner22,902,88823.72%Oct 27, 2026
Richard P. BlumbergDirector, 10% owner13,543,13014.03%May 5, 2026
Michael C. JamesDirector1,001,8631.04%Apr 7, 2026
Alan GrujicDirector1,817,5411.88%Apr 7, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
John E. Imhoff
Director, 10% owner
Sep 30, 2026Conversion+1,650,215$0.07$115.52K22,902,888
John E. Imhoff
Director, 10% owner
Mar 31, 2026Conversion+157,417$0.07$11.02K21,252,673
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other+1,040,000––10,020,273
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other−88––0
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other+19,038––10,039,311
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other+352,000––10,391,311
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other−260––0
Richard P. Blumberg
Director, 10% owner
Mar 26, 2026Other+56,093––8,980,273
John E. Imhoff
Director, 10% owner
Mar 26, 2026Other−10––0
John E. Imhoff
Director, 10% owner
Mar 26, 2026Other+2,157––21,055,256
John E. Imhoff
Director, 10% owner
Mar 26, 2026Other+40,000––21,095,256
John E. Imhoff
Director, 10% owner
Feb 27, 2026Other−100––0
John E. Imhoff
Director, 10% owner
Feb 27, 2026Other+400,000––20,897,013
John E. Imhoff
Director, 10% owner
Feb 27, 2026Conversion+156,086$0.07$10.93K21,053,099
Richard P. Blumberg
Director, 10% owner
Feb 25, 2026Option exercise+1,000,000––8,924,180
John E. Imhoff
Director, 10% owner
Feb 25, 2026Option exercise+500,000––20,497,013
Michael C. James
Director
Feb 25, 2026Option exercise+100,000––653,495
John E. Imhoff
Director, 10% owner
Feb 2, 2026Conversion+312,720$0.07$21.89K19,997,013
John E. Imhoff
Director, 10% owner
Jan 5, 2026Other+25,338––19,684,293
John E. Imhoff
Director, 10% owner
Dec 18, 2025Conversion+195,460$0.07$13.68K19,658,955
Alan Grujic
Director
Aug 29, 2025Buy+152,108––1,817,541
John E. Imhoff
Director, 10% owner
Aug 29, 2025Buy+166,667$0.18$30.00K19,463,495
Michael C. James
Director
Aug 29, 2025Buy+27,778$0.18$5.00K553,495
Alan Grujic
Director
Aug 21, 2025Other+200,000––1,665,433
Alan Grujic
Director
Aug 21, 2025Other+17,408––1,465,433
Alan Grujic
Director
Aug 21, 2025Other−50––0
John E. Imhoff
Director, 10% owner
Aug 21, 2025Other−300––100
John E. Imhoff
Director, 10% owner
Aug 21, 2025Other+104,448––18,096,828
John E. Imhoff
Director, 10% owner
Aug 21, 2025Other+1,200,000––19,296,828
Richard P. Blumberg
Director, 10% owner
Aug 21, 2025Other+932,000––7,924,180
Richard P. Blumberg
Director, 10% owner
Aug 21, 2025Other−233––0
Richard P. Blumberg
Director, 10% owner
Aug 21, 2025Other+81,121––6,992,180
Richard P. Blumberg
Director, 10% owner
Apr 10, 2025Other+55,853––6,911,059
Richard P. Blumberg
Director, 10% owner
Apr 10, 2025Other+165,481––6,855,206
John E. Imhoff
Director, 10% owner
Apr 10, 2025Other+6,365––17,992,380
John E. Imhoff
Director, 10% owner
Apr 10, 2025Other+6,365––17,992,380
John E. Imhoff
Director, 10% owner
Mar 18, 2025Buy+1,000,000$0.10$100.00K17,722,946
John E. Imhoff
Director, 10% owner
Mar 18, 2025Buy+263,069$0.10$26.31K17,986,015
John E. Imhoff
Director, 10% owner
Mar 18, 2025Buy+263,069$0.10$26.31K17,986,015
John E. Imhoff
Director, 10% owner
Mar 18, 2025Buy+1,000,000$0.10$100.00K17,722,946
Michael C. James
Director
Mar 18, 2025Buy+150,000$0.10$15.00K262,772
Michael C. James
Director
Mar 18, 2025Buy+262,945$0.10$26.29K525,717
John E. Imhoff
Director, 10% owner
Mar 13, 2025Buy+150––400
John E. Imhoff
Director, 10% owner
Mar 11, 2025Other−286––0
John E. Imhoff
Director, 10% owner
Mar 11, 2025Other+2,258,690$0.13$293.63K16,722,946
John E. Imhoff
Director, 10% owner
Mar 11, 2025Other−286––0
John E. Imhoff
Director, 10% owner
Mar 11, 2025Other+2,258,690$0.13$293.63K16,722,946
John E. Imhoff
Director, 10% owner
Mar 7, 2025Buy+286––286
John E. Imhoff
Director, 10% owner
Mar 7, 2025Buy+286––286
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other+4,801,500$0.50$2.40M14,464,256
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other−2,400.75––0
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other−300––0
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other+900,000––9,662,756
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other+4,801,500$0.50$2.40M14,464,256
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other−300––0
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other−2,400.75––0
John E. Imhoff
Director, 10% owner
Mar 6, 2025Other+900,000––9,662,756
John E. Imhoff
10% owner
Jan 17, 2025Other+35,312––8,762,756
John E. Imhoff
Director, 10% owner
Dec 18, 2024Buy+1,615,385––8,727,444
John E. Imhoff
Director, 10% owner
Oct 15, 2024Other+36,161––7,112,059

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+63.4%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Guided Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,275 shares on Sep 22, 2026 over the last 90 days.

See a number that looks wrong?